1. US National Library of Medicine. ClinicalTrials.gov: Cannabis studies. Accessed September 1, 2021: https://clinicaltrials.gov/ct2/results?cond=&term=Cannabis&cntry=&state=&city=&dist=


2. Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015 Oct;12(4): 692-8.

3. Woodhams SG, Chapman V, Finn DP, Hohmann AG, Neugebauer V. The cannabinoid system and pain. Neuropharmacology. 2017 Sep; 124: 105-120.

4. Health Canada. Information for Health Care Professionals: Cannabis and the cannabinoids. October 2018. ISBN: 978-0-660-27828-5.

5. Häuser W, Finn DP, Kalso E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018 Oct;22(9): 1547-64.


6. Centonze D. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways.Eur Neurol. 2014 Sep;72 Suppl 1: 6-8.

7. Solari A, Giordano A, Sastre-Garriga J, et al. EAN guideline on palliative care of people with severe, progressive multiple sclerosis. Eur J Neurol. 2020 Aug;27(8): 1510-29.


8. Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle. 2015 Dec;6(4): 287-302.

9. Radbruch L, Elsner F, Trottenberg P, Strasser F, Fearon K. Clinical Practice Guidelines on Cancer Cachexia in Advanced Cancer Patients. Aachen, Department of Palliative Medicine: European Palliative Care Research Collaborative; 2010.

10. Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1): 11-48.


11. Martin BR, Wiley JL. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol. 2004 Jul-Aug;2(4): 305-14; discussion 314-6.

12. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001 Jul 7;323(7303):16-21.

13. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015 Jun 23-30;313(24): 2456-73. Erratum in: JAMA. 2015 Aug 4;314(5):520. Erratum in: JAMA. 2015 Aug 25;314(8):837. Erratum in: JAMA. 2015 Dec 1;314(21): 2308. Erratum in: JAMA. 2016 Apr 12;315(14): 1522.

14. Berger MJ, Ettinger DS, Aston J, et al. NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017 Jul;15(7): 883-893.


15. Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res. 2017 Dec;7(2): 61-76.

16. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and epilepsy. Neurotherapeutics. 2015 Oct;12(4): 747-68.

17. Epidyolex® Summary of Product Characteristics. GW Pharma. July 2021.

18. McCoy B, Wang L, Zak M, et al. A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome. Ann Clin Transl Neurol. 2018 Aug;5(9); 1077-88.

19. Huntsman RJ, Tang-Wai R, Alcorn J, et al. Dosage related efficacy and tolerability of cannabidiol in children with treatment-resistant epileptic encephalopathy: preliminary results of the CARE-E study. Front Neurol. 2019 Jul; 10: 716.

20. Tzadok M, Uliel-Siboni S, Linder I, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure. 2016; 35: 41-44.

21. Caraballo R, Valenzuela GR. Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: A study of eight patients. Seizure. 2021 Nov;92: 238-243.